Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme

Molecular Neurodegeneration

Volumn 4, Issue 1, 2009, Pages

  Delledonne, Anthony ^a   Kouri, Naomi ^a   Reinstatler, Lael ^a   Sahara, Tomoko ^a   Li, Lilin ^b   Zhao, Ji ^b   Dickson, Dennis W ^a   Ertekin Taner, Nilufer ^a,b,c   Leissring, Malcolm A ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6A1; MONOCLONAL ANTIBODY 6H9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

EID: 79960102780     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-4-39     Document Type: Article

References (14)

1. Duckworth WC, Bennett RG, Hamel FG: Insulin degradation: progress and potential. Endocr Rev 1998, 19:608-624.
2. Hersh LB: The insulysin (insulin degrading enzyme) enigma. Cell Mol Life Sci 2006, 63:2432-2434.
3. Malito E, Hulse RE, Tang WJ: Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell Mol Life Sci 2008, 65:2574-2585.
4. Selkoe DJ: Clearing the brain's amyloid cobwebs. Neuron 2001, 32:177-180.
5. Leissring MA: The AβCs of Aβ-cleaving proteases. J Biol Chem 2008, 283:29645-29649.
6. Fakhrai-Rad H, Nikoshkov A, Kamel A, Fernstrom M, Zierath JR, Norgren S, Luthman H, Galli J: Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. Hum Mol Genet 2000, 9:2149-2158.
7. Karamohamed S, Demissie S, Volcjak J, Liu C, Heard-Costa N, Liu J, Shoemaker CM, Panhuysen CI, Meigs JB, Wilson P, et al.: Polymorphisms in the insulin-degrading enzyme gene are associated with type 2 diabetes in men from the NHLBI Framingham Heart Study. Diabetes 2003, 52:1562-1567.
8. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ: Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol 2004, 164:1425-1434.
9. Li Q, Ali MA, Cohen JI: Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread. Cell 2006, 127:305-316.
10. Leissring MA, Farris W, Wu X, Christodoulou DC, Haigis MC, Guarente L, Selkoe DJ: Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem J 2004, 383:439-446.
11. Authier F, Cameron PH, Merlen C, Kouach M, Briand G: Endosomal proteolysis of glucagon at neutral pH generates the bioactive degradation product miniglucagon-( 19- 29). Endocrinology 2003, 144:5353-5364.
12. Zhao J, Li L, Leissring MA: Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. Mol Neurodegener 2009, 4:4.
13. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ: Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 2000, 20:1657-1665.
14. Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ: Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry 2005, 44:6513-6525.